115 related articles for article (PubMed ID: 36473310)
1. Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown.
Gao Y; Gong Y; Liu Y; Xue Y; Zheng K; Guo Y; Hao L; Peng Q; Shi X
Acta Histochem; 2023 Jan; 125(1):151987. PubMed ID: 36473310
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.
Peng Q; Hao L; Guo Y; Zhang Z; Ji J; Xue Y; Liu Y; Li C; Lu J; Shi X
J Nat Med; 2023 Jan; 77(1):28-40. PubMed ID: 36068393
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
[TBL] [Abstract][Full Text] [Related]
4. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
5. miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma.
Ren K; Li T; Zhang W; Ren J; Li Z; Wu G
J Biomed Sci; 2016 Nov; 23(1):79. PubMed ID: 27832779
[TBL] [Abstract][Full Text] [Related]
6. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin inhibited interleukin-18 expression by decreasing YAP1 in hepatocellular carcinoma cells.
Gong Y; Peng Q; Gao Y; Yang J; Lu J; Zhang Y; Yang Y; Liang H; Yue Y; Shi X
Acta Histochem; 2023 May; 125(4):152040. PubMed ID: 37119608
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8
Gao Y; Gong Y; Lu J; Yang Y; Zhang Y; Xiong Y; Shi X
Biochem Pharmacol; 2024 Jul; 225():116294. PubMed ID: 38754557
[TBL] [Abstract][Full Text] [Related]
9. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
Guo C; Wang X; Liang L
Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
[TBL] [Abstract][Full Text] [Related]
10. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
[TBL] [Abstract][Full Text] [Related]
11. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.
Guo C; Zhou S; Yi W; Yang P; Li O; Liu J; Peng C
Exp Mol Pathol; 2021 Jun; 120():104638. PubMed ID: 33878313
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-345 inhibits hepatocellular carcinoma metastasis by inhibiting YAP1.
Zhang H; Liu H; Bi H
Oncol Rep; 2017 Aug; 38(2):843-849. PubMed ID: 28677785
[TBL] [Abstract][Full Text] [Related]
14. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
15. YAP1 suppression inhibits autophagy and improves the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
Gao Y; Peng Q; Li S; Zheng K; Gong Y; Xue Y; Liu Y; Lu J; Zhang Y; Shi X
Exp Cell Res; 2023 Mar; 424(1):113486. PubMed ID: 36693491
[TBL] [Abstract][Full Text] [Related]
16. miR-424-5p Regulates Hepatoma Cell Proliferation and Apoptosis.
Piao L; Wang F; Wang Y; Yang Z; Li Q; Cui L; Yu Q
Cancer Biother Radiopharm; 2019 Apr; 34(3):196-202. PubMed ID: 30676784
[TBL] [Abstract][Full Text] [Related]
17. Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease.
Simile MM; Latte G; Demartis MI; Brozzetti S; Calvisi DF; Porcu A; Feo CF; Seddaiu MA; Daino L; Berasain C; Tomasi ML; Avila MA; Feo F; Pascale RM
Oncotarget; 2016 Aug; 7(31):49194-49216. PubMed ID: 27359056
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis.
Lu X; Gan Q; Gan C; Zheng Y; Cai B; Li X; Li D; Yin G
Life Sci; 2021 Jun; 274():118303. PubMed ID: 32841663
[TBL] [Abstract][Full Text] [Related]
19. Role of RBM3 in the regulation of cell proliferation in hepatocellular carcinoma.
Miao X; Zhang N
Exp Mol Pathol; 2020 Dec; 117():104546. PubMed ID: 32976820
[TBL] [Abstract][Full Text] [Related]
20. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR‑375 sponging.
Zhao L; Lou G; Li A; Liu Y
Mol Med Rep; 2020 Aug; 22(2):1449-1457. PubMed ID: 32626943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
